Application of hydroxysafflor yellow A in preparation of ferroptosis inhibitor
By regulating the NF2-YAP signaling pathway, hydroxysafflower yellow pigment A upregulates NF2 and downregulates the expression of proteins such as YAP, and develops it as a ferrodysfunction inhibitor, solving the problem of insufficient ferrodysfunction inhibitors in the existing technology, and achieving ferrodysfunction-related diseases effective treatment.
Patent Information
- Application Number
- CN202411256205.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-11-08
Smart Images

Figure CN118903097A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine technology, and in particular to application of hydroxysafflor yellow A in the preparation of ferroptosis inhibitors. Background Art
[0002] Ferroptosis is caused by iron ions (Fe 2+ )-dependent accumulation of lipid hydroperoxides, with obvious iron accumulation; and the process can be effectively inhibited by iron chelators and lipophilic antioxidants but not by inhibitors of classic cell death forms such as apoptosis, pyroptosis and autophagy. The main mechanism of ferroptosis is that under the action of divalent iron or esteroxygenase, unsaturated fatty acids highly expressed on the cell membrane are catalyzed to cause lipid peroxidation, thereby inducing cell death; in addition, it is also manifested as a decrease in GPX4, the core enzyme regulating the antioxidant system (glutathione system).
[0003] Since the discovery of ferroptosis, as people have studied its mechanism in depth, it has been recognized as a regulatable cell death mode. Studies by WU et al. have shown that the sensitivity of cells to ferroptosis can be affected by regulating the NF2 (Merlin)-YAP pathway. At present, the main key regulatory sites of ferroptosis include: acyl-CoA synthetase long-chain family member 4 (ACSL4) in the lipid metabolism pathway, GPX4 in the amino acid metabolism pathway, and transferrin receptor 1 (TFR1) in the iron metabolism pathway. In addition, ferroptosis inducers Erastin and Ras-selective lethal small molecule 5 (RSL5) can directly bind to the mitochondrial voltage-dependent anion channel (VDAC) on the mitochondrial membrane to generate reactive oxygen species (ROS) and induce ferroptosis.
[0004] Cellular ferroptosis is closely related to the occurrence and development of neurodegenerative diseases, tissue ischemia-reperfusion injury, stroke, cardiovascular and renal failure, and diabetic complications. Ferroptosis inhibitors are considered to be potential drugs for the treatment of these diseases. It is very necessary to develop new ferroptosis inhibitors.
[0005] Hydroxysafflor yellow A (HSYA) is a flavonoid compound isolated from the Chinese herbal medicine safflower, with a molecular formula of C 27 H 32 O 16, the structural formula is as follows:
[0006]
[0007] Hydroxysafflor yellow A has multiple pharmacological effects such as scavenging free radicals, promoting blood circulation and menstruation, removing blood stasis and relieving pain, anti-platelet aggregation, and anti-oxidation. So far, there has been no report on the development of hydroxysafflor yellow A as a ferroptosis inhibitor. Summary of the invention
[0008] The purpose of the present invention is to provide an application of hydroxysafflor yellow A in the preparation of ferroptosis inhibitors to solve the problems existing in the above-mentioned prior art. The present invention has found that hydroxysafflor yellow A can inhibit cell ferroptosis by regulating the NF2-YAP signaling pathway, so hydroxysafflor yellow A can be used to prepare ferroptosis inhibitors.
[0009] To achieve the above object, the present invention provides the following solutions:
[0010] The present invention provides application of hydroxysafflor yellow A in preparing a ferroptosis inhibitor.
[0011] Furthermore, the hydroxysafflor yellow A inhibits cell ferroptosis by regulating the NF2-YAP pathway.
[0012] Furthermore, the regulation of the NF2-YAP pathway refers to upregulating the expression level of NF2 protein and downregulating the expression level of YAP protein.
[0013] The invention also provides a ferroptosis inhibitor, wherein the active ingredient comprises hydroxysafflor yellow A.
[0014] The present invention also provides the use of the above-mentioned ferroptosis inhibitor in the preparation of a drug for treating diseases related to ferroptosis.
[0015] The present invention also provides a medicine for treating diseases related to ferroptosis, wherein the active ingredient includes the above-mentioned ferroptosis inhibitor.
[0016] Furthermore, the medicine also includes pharmaceutically acceptable excipients.
[0017] Furthermore, the dosage form of the drug is tablets, granules, powders, emulsions, capsules or injections.
[0018] The present invention discloses the following technical effects:
[0019] The present invention found that hydroxysafflor yellow A can inhibit cell ferroptosis by regulating the NF2-YAP signaling pathway, specifically by downregulating the expression levels of YAP, TFR1, VDAC2 and VDAC3 proteins, and upregulating the expression levels of NF2 and GPX4 proteins. Therefore, hydroxysafflor yellow A can be used to prepare ferroptosis inhibitors.
[0020] The present invention develops a new approach for preparing ferroptosis inhibitors and has important practical application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0022] Figure 1 It is HSYA, H 2 O 2 The results of the test on the effect of HSYA and Erastin on the activity of HUVEC cells; A is the effect of HSYA alone; B is the effect of H 2 O 2 Acting alone; C is Erastin acting alone; D is H 2 O 2 Acts simultaneously with HSYA; E stands for Erastin and HSYA acting simultaneously; # p<0.05vs. blank control group; ## p<0.01vs. blank control group; ** p<0.01vs. model group;
[0023] Figure 2 It's HSYA vs H 2 O 2 Effects of MDA (A), T-AOC (B), SOD (C) and GSH (D) contents in the induced HUVEC cell injury model; ## p<0.01vs. blank control group; * p<0.05vs. model group; ** p<0.01vs. model group;
[0024] Figure 3 HSYA is respectively 2 O 2 The results of the detection of mitochondrial damage of HUVEC cells induced by erastin (×200); A is the Control group; B is the HSYA (160μmol / L) group; C is the H 2O 2 Group; D is H 2 O 2 +HSYA (40μmol / L) group; E is H 2 O 2 +HSYA (80μmol / L) group; F is H 2 O 2 +HSYA (160 μmol / L) group; G is Erastin group; H is Erastin2+HSYA (40 μmol / L) group; I is Erastin+HSYA (80 μmol / L) group; J is Erastin+HSYA (160 μmol / L) group;
[0025] Figure 4 HSYA acts on H 2 O 2 The results of the detection of NF2 and YAP protein and mRNA expression levels in induced HUVEC cells; A and B are the Western blot detection results and protein level statistics, respectively; C is the statistical chart of mRNA expression levels; ## p<0.01vs. blank control group; * p<0.05vs. model group; ** p<0.01vs. model group;
[0026] Figure 5 HSYA acts on H 2 O 2 Detection results of the expression levels of ferroptosis-related proteins VDAC2 / 3, GPX4 and TFR1 in induced HUVEC cells; A is the Western blot detection result of VDAC2 and VDAC3 proteins; C is the protein level statistical graph of A; B is the Western blot detection result of GPX4 and TFR1 proteins; D is the protein level statistical graph of B; ## p<0.01vs. blank control group; * p<0.05vs. model group; ** p<0.01vs. model group;
[0027] Figure 6 The results of the detection of NF2 and YAP protein and mRNA expression levels after HSYA acted on Erastin-induced HUVEC cells; A and B are the Western blot detection results and protein level statistics, respectively; C is the mRNA expression level statistics; ## p<0.01vs. blank control group; * p<0.05vs. model group; ** p<0.01vs. model group;
[0028] Figure 7 These are the results of the detection of the expression levels of ferroptosis-related proteins VDAC2 / 3, GPX4, and TFR1 proteins after HSYA acted on Erastin-induced HUVEC cells; A is the Western blot detection result of VDAC2 and VDAC3 proteins; C is the protein level statistical graph of A; B is the Western blot detection result of GPX4 and TFR1 proteins; D is the protein level statistical graph of B; ## p<0.01vs. blank control group; * p<0.05vs. model group; ** p<0.01vs. model group;
[0029] Figure 8 Is HSYA to H after si-NF2 2 O 2 The effects of induced cell ferroptosis-related proteins NF2, YAP, VDAC2 / 3, GPX4, and TFR1 on their expressions; A is the Western blot test result of NF2 and YAP proteins; D is the protein level statistical chart of A; B is the Western blot test result of VDAC2 and VDAC3 proteins; E is the protein level statistical chart of B; C is the Western blot test result of GPX4 and TFR1 proteins; F is the protein level statistical chart of C; ## p<0.01vs. blank control group; ** p<0.01vs. model group;
[0030] Fig. 9 The effect of HSYA after si-NF2 on the expression of Erastin-induced ferroptosis-related proteins NF2, YAP, VDAC2 / 3, GPX4, and TFR1; A is the Western blot detection result of NF2 and YAP proteins; D is the protein level statistical graph of A; B is the Western blot detection result of VDAC2 and VDAC3 proteins; E is the protein level statistical graph of B; C is the Western blot detection result of GPX4 and TFR1 proteins; F is the protein level statistical graph of C; ## p<0.01vs. blank control group; ** p<0.01vs. model group;
[0031] Fig.10 Is HSYA to H after si-YAP 2 O 2The effects of induced cell ferroptosis-related proteins YAP, VDAC2 / 3 and TFR1 on expression; A is the Western blot detection result of YAP and TFR1 proteins; C is the protein level statistical chart of A; B is the Western blot detection result of VDAC2 and VDAC3 proteins; D is the protein level statistical chart of B; ## p<0.01vs. blank control group; ** p<0.01vs. model group. DETAILED DESCRIPTION
[0032] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0033] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0034] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0035] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.
[0036] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0037] Terminology Note:
[0038] NF2 refers to neurofibromin 2;
[0039] YAP refers to a multifunctional intracellular junction protein and transcriptional coactivator named Yes-associated protein.
[0040] Example 1 Ferroptosis Inhibition Effect of Hydroxysafflor Yellow A
[0041] 1. Culture of human umbilical vein endothelial cells (HUVEC)
[0042] After taking out the HUVEC cell cryopreservation tube from the liquid nitrogen tank, quickly insert it into a 37°C water bath and shake it continuously to completely dissolve it within 1 minute. In a sterile clean bench, use a pipette to transfer the cell suspension to a centrifuge tube containing 2mL of culture medium, gently blow and mix, then seal it and centrifuge it at 1200g for 5 minutes at room temperature. After centrifugation, carefully aspirate the supernatant and discard it, and slowly add 4mL of culture medium into the centrifuge tube and blow and mix. Aspirate the mixed cell suspension into a new cell culture bottle and carefully blow the bottom of the bottle to allow the cells to grow evenly. Next, mark the cell culture bottle and place it in an incubator (37°C, 5% CO 2 ) and the medium can be changed after the cells are completely attached. When the cells cover about 90% of the bottom of the bottle, wash three times with PBS and use 0.25% trypsin solution for digestion and passage.
[0043] Digest with 1 mL of 0.25% pancreatic enzyme solution for about 2 minutes, add 1 mL of cell culture medium containing FBS to terminate digestion, blow off the cells at the bottom of the bottle and suck them into a centrifuge tube for centrifugation. Discard the supernatant, add 1 mL of cell freezing solution to resuspend the cells and transfer them into a cryopreservation tube. After gradient cooling, place them in a liquid nitrogen tank for long-term storage.
[0044] 2. MTT assay to determine cell activity
[0045] 2.1 Determination of endothelial cell activity after HSYA treatment
[0046] The seeding density in a 96-well plate is approximately 8 × 10 3 / mL HUVEC cells were cultured in an incubator for 24 hours. A complete blank group, a control group and a drug group were set up, with 6 replicates in each group. Different concentrations of HSYA (10, 20, 40, 80, 160 and 320 μmol / L) were added to the drug group, and the culture medium was discarded after incubation in the incubator for 24 hours. Under light-proof conditions, CCK8 solution was prepared according to the instructions and added to each well, and the incubator was continued for 2 hours. The survival rate of each group of cells was calculated based on the measured absorbance value, and the most suitable HSYA concentration was selected as the drug concentration.
[0047] 2.2H 2 O 2 Effects of Erastin on HUVEC Cell Activity
[0048] The seeding density in a 96-well plate is approximately 8 × 103 HUVEC cells were cultured in an incubator for 24 h. 2 O 2 62.5, 125, 250, 500, 1000, 2000 μmol / L) and different concentrations of ferroptosis activator Erastin (1.25, 2.5, 5, 10, 20, 40 μmol / L) were added to a 96-well plate, and a complete blank group and a control group were set up with 6 replicates in each group. After incubation in the incubator for 24 hours, the cell activity was detected according to step 2.1, and the most suitable H 2 O 2 The concentration of Erastin was used as the modeling concentration.
[0049] 2.3HSYA vs H 2 O 2 Effects of Erastin on the Activity of HUVEC Cells Induced by Damage
[0050] HUVEC cells were seeded in 96-well plates at a density of approximately 8 × 10 3 / mL, and incubate for 24h. Set up a complete blank group, a control group, and H 2 O 2 Injury group (500 μmol / L), H 2 O 2 +HSYA (20, 40, 80, 160 μmol / L) group, as well as the complete blank group, control group, Erastin injury group (10 μmol / L), Erastin + HSYA (20, 40, 80, 160 μmol / L) group, and each group was set up with 6 replicates. After incubation in the incubator for 24 hours, the cell activity was detected to determine the low, medium and high doses of HSYA.
[0051] 2.4HSYA,H 2 O 2 , Erastin concentration setting results
[0052] Depend on Figure 1 As shown in Figure A, compared with the blank control group, the cell viability decreased significantly after 24 hours of treatment with 320 μmol / L HSYA. There was no significant change in cell viability after 24 hours of treatment with HSYA at a concentration of 160 μmol / L or less, indicating that HSYA at a concentration of 160 μmol / L or less had no significant toxicity to cells, so it could be selected as the experimental drug concentration. Figure 1 Results in B and C show H 2 O 2 Both dapoxetine and erastin inhibited the proliferation of HUVEC cells in a dose-dependent manner. Figure 1 The results in B show that when H 2 O2 When the concentration was 250 μmol / L, the cell survival rate was 82.4%, and when the concentration was 500 μmol / L, the cell survival rate was 64.8%. Therefore, 500 μmol / L was selected as the H 2 O 2 Optimal modeling concentration. Figure 1 The results in Figure 3 showed that when the concentration of Erastin was 5 μmol / L, the cell survival rate was 83.8%, and when the concentration was 10 μmol / L, the cell survival rate was 61.7%. Therefore, 10 μmol / L was selected as the optimal concentration of Erastin for modeling. Figure 1 D and E show that compared with the model group, after treatment with 20, 40, 80, and 160 μmol / L HSYA, H 2 O 2 The damaging effects of HSYA and Erastin on cells were significantly reduced, and the cell survival rate was significantly increased. Therefore, 40, 80, and 160 μmol / L were selected as the low, medium, and high dose groups of HSYA.
[0053] 3. Determination of biochemical indicators
[0054] 3.1 Grouping and Methods
[0055] HUVEC cells were seeded in 6-well plates at a density of approximately 8 × 10 3 / mL, and incubate for 24h. Then the six-well plate was divided into blank control group, HSYA (160μmol / L) group, H 2 O 2 (500μmol / L) group, H 2 O 2 +HSYA (40 μmol / L) group, H 2 O 2 +HSYA (80 μmol / L) group and H 2 O 2 +HSYA (160 μmol / L) group. After 24 hours of continuous culture, the cells were collected and disrupted by ultrasonication according to the instructions. The cells were centrifuged in a centrifuge (12000g, 4°C) for 10 minutes, and the supernatant was used for determination. The cell protein concentration was determined by BCA determination. The content of relevant biochemical indicators was determined according to the steps and calculation formulas in the instructions.
[0056] 3.2 Results of biochemical indexes
[0057] like Figure 2As shown in the figure, the MDA level in HUVEC cells of the model group was significantly higher than that of the blank control group, while the levels of T-AOC, SOD and GSH were significantly lower. The MDA content in the treatment groups given different doses of HSYA was significantly lower than that of the model group, while the contents of T-AOC, SOD and GSH were significantly increased in a dose-dependent manner, indicating that HSYA has a good antioxidant effect.
[0058] 4. HSYA vs. H 2 O 2 Effects of mitochondrial damage induced by β-lactamase and erastin on HUVEC cells
[0059] 4.1 Cell grouping and methods
[0060] The density is about 8×10 3 HUVEC cells (100 μmol / L) were inoculated in 6-well plates and cultured in an incubator for 24 h. 2 O 2 (500μmol / L) group, H 2 O 2 (500μmol / L)+HSYA (40, 80 and 160μmol / L) group, Erastin (10μmol / L) group, Erastin (10μmol / L)+HSYA (40, 80 and 160μmol / L) group, continue to culture for 24h, then wash and collect the cells and process according to the instructions. Finally, an inverted fluorescence microscope was used to observe and obtain the staining images.
[0061] 4.2HSYA vs. H 2 O 2 Results of Erastin-induced MMP in HUVECs
[0062] An important feature of ferroptosis is mitochondrial damage. JC-1 is a fluorescent probe for detecting MMP. MMP is beneficial to maintaining the normal physiological function of cells and is one of the important indicators for evaluating mitochondrial function. The higher the MMP, the more red fluorescence it will produce, which means that the mitochondria will produce more energy, which is beneficial to the energy conversion of cells. Figure 3 The results showed that compared with the blank control group, H 2 O 2 The green fluorescence of the HA group and Erastin group increased, indicating that MMP decreased. 2 O 2 +HSYA treatment group, Erastin+HSYA and H 2 O 2 Compared with the Erastin group, the red fluorescence gradually increased, indicating that MMP gradually increased. The above results show that HSYA has an effect on H 2 O2 It has a protective effect on the mitochondrial damage of HUVEC cells induced by Erastin.
[0063] 5. Determination of intracellular related protein expression levels by Western blot
[0064] 5.1 Cell grouping and protein extraction
[0065] HUVEC cells were seeded in 6-well plates at a density of approximately 8 × 10 3 After 24 h of incubation, the blank control group, HSYA (160 μmol / L) group, and H 2 O 2 (500μmol / L) group, H 2 O 2 +HSYA (40 μmol / L) group, H 2 O 2 +HSYA (80 μmol / L) group, H 2 O 2 +HSYA (160μmol / L) group and blank control group, HSYA (160μmol / L) group, Erastin (10μmol / L) group, Erastin+HSYA (40μmol / L) group, Erastin+HSYA (80μmol / L) group and Erastin+HSYA (160μmol / L) group treated cells, continued to culture for 24h, washed the six-well plate three times with PBS buffer, added 70μL of IP lysis solution containing PMSF to each well, reacted on ice for 15min. Use a cell scraper to scrape the six-well plate and collect the cell lysate in a centrifuge tube, centrifuge for 10min on a centrifuge (12000g, 4℃), and retain the supernatant (total cell protein).
[0066] 5.2 Cellular protein quantification and denaturation
[0067] The steps for cell protein quantification and denaturation are as follows:
[0068] Draw a standard curve according to the BCA method and obtain the standard equation. Obtain the A570 value of the sample to be tested according to the same operation method, substitute it into the standard equation to calculate the protein concentration of the sample to be tested. Dilute the protein with PBS to adjust the protein to the same concentration, add the same volume of 2× Loading buffer as the protein sample after concentration adjustment, put it in boiling water and cook for 5 minutes to denature the protein sample for subsequent experiments, and store it in a -20℃ refrigerator for later use.
[0069] Nuclear protein extraction was performed according to the instructions of the nuclear protein extraction kit.
[0070] 5.3 Western blot detection
[0071] The steps for Western blot detection are as follows:
[0072] Prepare SDS-PAGE separation gel of appropriate concentration according to the molecular weight of the target protein; prepare 5% concentrated gel according to the formula. Place a clean glass plate on the gel rack, first pour the separation gel into the glass plate, then pour the concentrated gel into the glass plate after solidification, and insert the sample comb for use.
[0073] When loading the sample, take out the gel plate and place it in the electrophoresis tank, and add the electrophoresis solution. Use a microinjector to add 20μL of the target protein to each well, and add 3μL of protein pre-stained Marker solution to the reserved well. Then connect the power supply to start electrophoresis, set the current to 80mA, and stop the electrophoresis when the color of bromophenol blue reaches the bottom. Separate the glass plate, take out the gel, determine the position of the target protein according to the color of the Marker, cut the target protein required for the experiment, and soak it in the transfer buffer.
[0074] Since the widths of proteins with different molecular weights on the gel are different, the PVDF membrane is cut into strips of appropriate length and width in advance according to the molecular weight of the target protein. The PVDF membrane is soaked in methanol for about 15 seconds, and then soaked in transfer buffer. Soak the filter paper in the transfer buffer, first place the filter paper on the transfer clip, then place the PVDF membrane on the positive electrode and the gel on the negative electrode. Set the transfer time according to the molecular weight of the target protein, and the current is 300mA.
[0075] After the transfer is stopped, take out the PVDF membrane, put it into the blocking solution, and place it on a shaker for blocking for 2 hours.
[0076] Different antibodies were diluted to the most suitable concentration with TTBS, and the PVDF membrane was placed in the primary antibody overnight at 4°C. The next day, the PVDF membrane was removed from the primary antibody and washed in TTBS for 30 minutes, changing the solution every 10 minutes. Then, the membrane was placed in PBS and washed for 30 minutes, changing the solution every 10 minutes.
[0077] After dilution of the secondary antibody, place it on a shaker for 2 hours, take it out and image it with TTBS using an automatic gel system and develop it with an ECL kit. The grayscale results of the protein bands can be analyzed using GELPRO4, Image Lab software; the grayscale ratio of the target protein to β-actin is the result.
[0078] 5.4HSYA vs. H 2 O 2 Effects of induced NF2-YAP pathway on HUVEC cells
[0079] Depend on Figure 4 As shown in Figures A and B, compared with the blank control group, H2 O 2 In the model group, the protein expression level of NF2 was significantly decreased, while the protein expression level of YAP was significantly increased. After treatment with different doses of HSYA, the protein expression of NF2 was upregulated and the protein expression of YAP was downregulated.
[0080] 5.5HSYA vs. H 2 O 2 Effect of induced ferroptosis marker protein expression in HUVEC cells
[0081] Depend on Figure 5 It can be seen that H 2 O 2 In the model group, the protein expression levels of VDAC2 / 3 and TFR1 were significantly increased, while the protein expression level of GPX4 was significantly decreased. After administration of different doses of HSYA, the protein expression level of GPX4 was upregulated, while the protein expression levels of VDAC2 / 3 and TFR1 were downregulated. The above results suggest that HSYA can inhibit the 2 O 2 Induced ferroptosis in HUVEC cells.
[0082] Effect of HSYA on Erastin-induced NF2-YAP pathway in HUVEC cells
[0083] Erastin is a classic ferroptosis inducer that can cause ferroptosis in cells. Figure 6 As shown in Figures A and B, compared with the blank control group, the protein expression level of NF2 in the Erastin model group was significantly reduced, while the protein expression level of YAP was significantly increased. After treatment with different doses of HSYA, the protein expression of NF2 was upregulated, while the protein expression of YAP was downregulated.
[0084] Effect of HSYA on the expression of ferroptosis marker proteins in Erastin-induced HUVEC cells
[0085] Depend on Figure 7 It can be seen that the protein expression levels of VDAC2 / 3 and TFR1 in the Erastin model group were significantly increased, while the protein expression level of GPX4 was significantly decreased. After treatment with different doses of HSYA, the protein expression level of GPX4 was upregulated and the protein expression of VDAC2 / 3 and TFR1 was downregulated. The above results suggest that HSYA can inhibit the ferroptosis of HUVEC cells induced by Erastin.
[0086] 6. qRT-PCR method to determine the expression level of NF2 and YAP mRNA in cells
[0087] 6.1 Total RNA extraction from cells
[0088] The cells were grouped as in 5.1. After incubation for 24 hours, the six-well plate was washed three times with PBS buffer, and 0.5 mL of TransZol Up was added to each well. The plate was left standing for a while at room temperature. The cells were scraped with a cell scraper, and the cell lysate was collected in a sterilized EP tube. The mixture was mixed and left standing for 5 minutes. The cell RNA was extracted and reverse transcribed to synthesize cDNA according to the following steps:
[0089] First, weigh 50 mg of aorta and wash it in saline. Then place the tissue in a high-pressure centrifuge tube, add 1 mL of Trizol, cut it into pieces and homogenize it. Let it stand at room temperature for 5 minutes, then centrifuge it at 12000g and 4℃ for 5 minutes. Pipette the supernatant into a new EP tube, add 200 μL of chloroform, and mix it upside down. At this time, the solution will appear milky white. Let it stand at room temperature for 5 minutes and centrifuge it for 10 minutes. Pipette the upper aqueous phase into another centrifuge tube, add isopropanol of the same volume as the supernatant, and shake it thoroughly to mix it evenly.
[0090] Let stand at room temperature for 10 minutes, centrifuge at 12000g, 4℃ for 10 minutes, and retain the white precipitate as total RNA. Add 1mL 75% ethanol, gently shake the centrifuge tube to wash the precipitate. Centrifuge at 12000g, 4℃ for 5 minutes, repeat 3 times. Finally, aspirate the remaining ethanol and add 30μL ddH 2 O to dissolve the precipitate. Use RNA concentration meter to measure RNA concentration. If OD 260 / OD 280 If the ratio is between 1.8 and 2.2, it indicates that the RNA purity is high.
[0091] An equal amount of RNA solution diluted to 1 μg / μL was taken from each group and operated using the TransStart First-Strand cDNA Synthesis SuperMix Kit according to the instructions, and reverse transcription amplification and real-time quantitative PCR were performed on an Applied Biosystems instrument.
[0092] 6.2qRT-PCR data analysis
[0093] qRT-PCR test results were analyzed by 2 -ΔΔct The primer sequences of NF2, YAP, and β-actin are shown in Table 2.
[0094] Table 2 Primer sequences
[0095]
[0096] 6.5 qRT-PCR determination of intracellular NF2 and YAP mRNA results
[0097] Figure 4The qRT-PCR results of C showed that HSYA could reduce the 2 O 2 The above results suggest that HSYA may regulate HUVEC cells by 2 O 2 The NF2-YAP pathway plays a cytoprotective role in the induced HUVEC cell injury model.
[0098] Figure 6 The qRT-PCR results in C showed that HSYA could reduce the level of YAP mRNA and increase the level of NF2 mRNA in Erastin-induced HUVEC cells. The above results suggest that HSYA may inhibit ferroptosis and protect cells by regulating the NF2-YAP pathway in the Erastin-induced HUVEC cell ferroptosis model.
[0099] 7. Effects of si-NF2 on the expression of related proteins in cells
[0100] 7.1 Cell Grouping and Methods
[0101] HUVEC cells were cultured at approximately 4 × 10 3 The cells were inoculated at a density of 100 / mL in a 6-well plate and cultured in an incubator. Lipofectamine 3000 reagent was used to transfect si-Con (control siRNA) and si-NF2 (siRNA that silences the NF2 gene) into the cells. 2 O 2 The induced cell injury model was divided into blank control + si-Con group, H 2 O 2 (500 μmol / L)+si-Con group, H 2 O 2 +HSYA (160 μmol / L) +si-Con group, si-NF2 group, H 2 O 2 +si-NF2 group, H 2 O 2 +HSYA (160μmol / L) + si-NF2 group; Erastin-induced cell injury model was divided into blank control + si-Con group, Erastin (10μmol / L) + si-Con group, Erastin + HSYA (160μmol / L) + si-Con group, si-NF2 group, Erastin + si-NF2 + si-Con group, Erastin + HSYA (160μmol / L) + si-NF2 group. After 48h of transfection, H 2 O 2The cells were treated with Erastin and HSYA, and the expressions of related proteins were detected by Western blot.
[0102] 7.2H 2 O 2 Results of NF2-YAP signaling pathway-related protein determination after si-NF2 in the model
[0103] In order to further explore the anti-ferroptosis effect of HSYA and its relevance to the regulation of NF2-YAP signaling pathway, the present invention used siRNA interference technology to knock down the key protein NF2. Figure 8 As shown, with H 2 O 2 Compared with group H 2 O 2 +si-NF2 group NF2, GPX4 protein content significantly decreased, YAP, TFR1, VDAC2 / 3 protein content significantly increased. 2 O 2 Compared with the +si-NF2 group, the inhibitory effect of HSYA on downstream proteins YAP, TFR1, VDAC2 / 3 and the activating effect on GPX4 were significantly weakened but not completely eliminated, indicating that after silencing NF2, the therapeutic effect of HSYA was significantly inhibited but not completely eliminated. The experimental results show that the anti-ferroptosis effect of HSYA is closely related to the effect on NF2 expression and there may be other potential sites.
[0104] 7.3 Results of NF2-YAP signaling pathway-related protein determination after si-NF2 in the Erastin model
[0105] In order to further explore the anti-ferroptosis effect of HSYA and its relevance to the regulation of NF2-YAP signaling pathway, the present invention used siRNA interference technology to knock down the key protein NF2. Fig. 9 As shown in the figure, compared with the Erastin group, the NF2 and GPX4 protein levels in the Erastin+si-NF2 group were significantly reduced, and the YAP, TFR1, and VDAC2 / 3 protein levels were significantly increased. After treatment with 160μmol / L HSYA, compared with the Erastin+si-NF2 group, the inhibitory effect of HSYA on downstream proteins YAP, TFR1, and VDAC2 / 3 and the activation effect on GPX4 were weakened but not completely eliminated, indicating that after silencing NF2, the therapeutic effect of HSYA was inhibited but not completely eliminated. The experimental results show that the anti-ferroptosis effect of HSYA is closely related to the effect on NF2 expression.
[0106] 8. Effects of si-YAP on the expression of related proteins in cells
[0107] 8.1 Cell grouping and processing
[0108] HUVEC cells were cultured at approximately 4 × 10 3 The cells were inoculated at a density of 100 / mL in a 6-well plate and cultured in an incubator. Lipofectamine 3000 reagent was used to transfect si-Con (control group siRNA) and si-YAP (siRNA silencing the YAP gene) into the cells. 2 O 2 (500 μmol / L)+si-Con group, H 2 O 2 +HSYA (160 μmol / L) +si-Con group, si-YAP group, H 2 O 2 +si-YAP group, H 2 O 2 +HSYA (160 μmol / L) + si-YAP group. Western blot was used to detect the expression of related proteins.
[0109] 8.2H 2 O 2 Results of NF2-YAP signaling pathway-related protein determination after si-YAP in the model
[0110] The present invention found through the results of si-NF2 that HSYA may also play an anti-ferroptosis role through other sites, so the present invention transfected si-YAP into HUVEC cells, and Western blot was used to detect the expression of YAP, TFR1, and VDAC2 / 3 proteins. Fig.10 As shown, compared with the model group, H 2 O 2 The protein contents of YAP, TFR1, and VDAC2 / 3 in the +si-YAP group were significantly reduced. 2 O 2 Compared with the +si-YAP group, the inhibitory effect of HSYA on the expression of YAP, TFR1, and VDAC2 / 3 proteins was significantly weakened or even disappeared.
[0111] In summary, in H 2 O 2 In the induced cell injury model, HSYA can jointly affect NF2 and YAP sites to affect the expression of downstream proteins, thereby exerting an anti-ferroptosis effect.
[0112] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. Application of hydroxysafflor yellow A in the preparation of ferroptosis inhibitors.
2. The use according to claim 1, characterized in that: The hydroxysafflor yellow A inhibits cell ferroptosis by regulating the NF2-YAP pathway.
3. The use according to claim 1, characterized in that: The regulation of the NF2-YAP pathway refers to upregulating the expression level of NF2 protein and downregulating the expression level of YAP protein.
4. A ferroptosis inhibitor, characterized in that The active ingredient includes hydroxysafflor yellow A.
5. Use of the ferroptosis inhibitor as claimed in claim 4 in the preparation of a drug for treating diseases associated with ferroptosis.
6. A drug for treating a disease associated with ferroptosis, characterized in that: The active ingredient comprises the ferroptosis inhibitor according to claim 4.
7. The drug according to claim 6, characterized in that The drug also includes pharmaceutically acceptable excipients.
8. The drug according to claim 7, characterized in that The dosage form of the medicine is tablet, granule, powder, emulsion, capsule or injection.
